title: [What’s new in dermato-oncology?].
abstract: During this year 2013, Onco-dermatology was the object of numerous publications, especially in the field of metastatic melanoma. Previous results concerning anti PD-1 have been consolidated. Studies concerning Mek inhibitors have been published with promising results in uveal melanoma. In metastatic melanoma two combinations showed great results: combination of ipilimumab and nivolumab and combination of B-RAF and MEK inhibitors. Some studies demonstrated efficacy of these new therapeutics (ipilimumab, vemurafenib and dabrafenib) in brain metastasis. Moreover, the year 2013 was marked by the increasing knowledge in the management of adverse events induced by these new treatments. In the field of basal cell carcinoma, after the publication of large scale studies, vismodegib, the inhibitor of the hedgehog signalling pathway, was approved by the European Medicines Agency.
authors.affiliation: Clinique dermatologique, CHU de Nantes, 1 place Alexis-Ricordeau, 44093 Nantes Cedex, France. Electronic address: gaelle.quereux@chu-nantes.fr.
authors.forename: G
authors.initials: G
authors.lastname: Quéreux
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy; D003131:Combined Modality Therapy; D003880:Dermatology; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008495:Medical Oncology; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D012878:Skin Neoplasms / Q000188:drug therapy / Q000628:therapy; D017216:Telemedicine / Q000639:trends
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors
keywords: Carcinoma; Carcinome; Focused therapy; Immunotherapy; Immunothérapie; Melanoma; Mélanome; Thérapie ciblée